Status:
COMPLETED
Results Comparison of Cervical Cancer Early Detection Using Cerviray With VIA Test
Lead Sponsor:
Universitas Padjadjaran
Conditions:
Cervical Cancer
Eligibility:
FEMALE
Brief Summary
Cervical cancer, primarily caused by Human Papilloma Virus (HPV), is a significant global health concern, ranking as the fourth most common cancer in women worldwide. In Indonesia, it stands as the se...
Detailed Description
The study involved 44 patients from various health centers in West Java Province. Cerviray® AI, Cerviray® AI Evaluation, and VIA tests were administered to high-risk women of childbearing age.
Eligibility Criteria
Inclusion
- high-risk women of childbearing age who would be screened for cervical cancer (by Cerviray AI examination, Cerviray AI evaluation, and VIA test) at 1 clinic and other 4 health centers
Exclusion
- incomplete data
- patient refusing to be examined
- patient refusing to participate in the study
Key Trial Info
Start Date :
March 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 31 2023
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT06518070
Start Date
March 1 2023
End Date
October 31 2023
Last Update
July 24 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Padjajaran University
Bandung, Indonesia